Key Points
- Director John Johnson sold 135,400 shares at an average price of $7.22 for a total of $977,588, trimming his stake by 16.25% to 698,083 shares; the transaction was disclosed in an SEC filing.
- Xeris shares were trading up ~4.7% (opened $7.34) with a market cap of about $1.22 billion, a negative P/E of -73.39, and a 12‑month range of $3.14 to $10.08.
- The stock has a consensus rating of "Moderate Buy" with an average price target of $9.50, and institutional investors (including Vanguard, Invesco and Nuveen) own roughly 42.75% of the company.
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS - Get Free Report) Director John Johnson sold 135,400 shares of the firm's stock in a transaction that occurred on Friday, December 19th. The stock was sold at an average price of $7.22, for a total transaction of $977,588.00. Following the sale, the director directly owned 698,083 shares in the company, valued at approximately $5,040,159.26. The trade was a 16.25% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website.
Xeris Biopharma Trading Up 4.7%
Shares of Xeris Biopharma stock opened at $7.34 on Friday. The company has a fifty day simple moving average of $7.88 and a 200-day simple moving average of $6.86. The stock has a market cap of $1.22 billion, a price-to-earnings ratio of -73.39 and a beta of 0.57. Xeris Biopharma Holdings, Inc. has a 12-month low of $3.14 and a 12-month high of $10.08.
Xeris Biopharma (NASDAQ:XERS - Get Free Report) last announced its quarterly earnings results on Thursday, November 6th. The company reported $0.00 earnings per share for the quarter, missing analysts' consensus estimates of $0.01 by ($0.01). The company had revenue of $74.38 million for the quarter, compared to analysts' expectations of $74.19 million. On average, analysts forecast that Xeris Biopharma Holdings, Inc. will post -0.41 earnings per share for the current fiscal year.
Hedge Funds Weigh In On Xeris Biopharma
A number of large investors have recently bought and sold shares of XERS. Cetera Investment Advisers acquired a new stake in shares of Xeris Biopharma in the 1st quarter worth $245,000. Vanguard Group Inc. lifted its position in Xeris Biopharma by 2.7% in the first quarter. Vanguard Group Inc. now owns 8,109,644 shares of the company's stock valued at $44,522,000 after purchasing an additional 210,581 shares during the period. Charles Schwab Investment Management Inc. lifted its position in Xeris Biopharma by 5.2% in the first quarter. Charles Schwab Investment Management Inc. now owns 423,775 shares of the company's stock valued at $2,327,000 after purchasing an additional 20,903 shares during the period. Invesco Ltd. boosted its holdings in Xeris Biopharma by 1,387.8% in the 1st quarter. Invesco Ltd. now owns 1,026,838 shares of the company's stock valued at $5,637,000 after purchasing an additional 957,822 shares in the last quarter. Finally, Nuveen LLC acquired a new position in Xeris Biopharma during the 1st quarter worth approximately $12,240,000. Hedge funds and other institutional investors own 42.75% of the company's stock.
Analyst Ratings Changes
A number of equities research analysts have weighed in on the company. Wall Street Zen cut Xeris Biopharma from a "strong-buy" rating to a "hold" rating in a research note on Saturday, November 8th. HC Wainwright reiterated a "buy" rating and issued a $10.00 price target on shares of Xeris Biopharma in a research report on Friday, November 7th. Zacks Research downgraded shares of Xeris Biopharma from a "strong-buy" rating to a "hold" rating in a research report on Thursday, October 30th. Piper Sandler lifted their price objective on shares of Xeris Biopharma from $6.00 to $8.00 and gave the company a "neutral" rating in a research note on Friday, November 7th. Finally, Barclays assumed coverage on shares of Xeris Biopharma in a report on Monday, December 8th. They issued an "overweight" rating and a $9.00 target price for the company. Six investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Xeris Biopharma has a consensus rating of "Moderate Buy" and an average price target of $9.50.
Check Out Our Latest Stock Report on Xeris Biopharma
Xeris Biopharma Company Profile
(
Get Free Report)
Xeris Biopharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine and orphan diseases. The company's proprietary formulation platform is designed to enable liquid stability of drugs that traditionally require reconstitution before injection. By eliminating the need for on-site mixing and simplifying administration, Xeris aims to improve patient safety, adherence, and convenience in high-need therapeutic areas.
The company's flagship product, Gvoke, is a ready-to-use liquid glucagon autoinjector and prefilled syringe that has been approved by the U.S.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
